From the Journals

Outcomes have improved for PAH in connective tissue disease


 

FROM ARTHRITIS & RHEUMATOLOGY

‘Still have to be aggressive at identifying the high-risk patients’

Commenting on the findings, Virginia Steen, MD, of the division of rheumatology at Georgetown University, Washington, said clinicians were finally seeing some significant changes over time in scleroderma-associated PAH.

Dr. Virginia Steen of Georgetown University, Washington

Dr. Virginia Steen

“Although some of it may be just early diagnosis, I think that the combination of early diagnosis and more aggressive treatment with combination medication is definitely making a difference,” Dr. Steen said in an interview. “The bottom line is that we as rheumatologists still have to be aggressive at identifying the high-risk patients, making an early diagnosis, and working with our pulmonary hypertension colleagues and aggressively treating these patients so we can make a long-term difference.”

The authors of an accompanying editorial said the meta-analysis’ findings showed the positive impact of early combination therapy and early diagnosis through proactive screening.

“It is notable because the present analysis again confirms that outcomes are worse in CTD-PAH than in idiopathic or familial forms of PAH, the impact of treatments should no longer be regarded as insignificant,” the editorial’s authors wrote. “This is a practice changing observation, especially now that many of the drugs are available in generic formulations and so the cost of modern PAH treatment has fallen at the same time as its true value is convincingly demonstrated.”

They also argued there was strong evidence for the value of combination therapies, both for PAH-targeted drugs used in combination and concurrent use of immunosuppression and drugs specifically for PAH in some patients with CTD-PAH.

However, they pointed out that not all treatments for idiopathic PAH were suitable for patients with CTDs, highlighting the example of anticoagulation that can improve survival in the first but worsen it in the second.

The study was funded by Actelion. Six authors declared funding and grants from the pharmaceutical sector, including the study sponsor, and three authors were employees of Actelion.

Pages

Recommended Reading

Treprostinil offers some benefits for patients with ILD-associated pulmonary hypertension
MDedge Rheumatology
Severe renal arteriosclerosis may indicate cardiovascular risk in lupus nephritis
MDedge Rheumatology
FDA approves voclosporin for lupus nephritis
MDedge Rheumatology
Palliative care underused in pulmonary arterial hypertension
MDedge Rheumatology
Meta-analysis finds much less lupus than expected
MDedge Rheumatology
Rheumatologic disease activity an important influencer of COVID-19 death risk
MDedge Rheumatology
Women increasingly turn to CBD, with or without doc’s blessing
MDedge Rheumatology
Checkpoint inhibitors’ ‘big picture’ safety shown with preexisting autoimmune diseases
MDedge Rheumatology
Tocilizumab may improve lung function in early systemic sclerosis
MDedge Rheumatology
Consider home subcutaneous immune globulin for refractory dermatomyositis
MDedge Rheumatology